Comparison of Major-Bleeding Risk and Health Care Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin

relationships.isProjectOf

relationships.isJournalIssueOf

Yükleniyor...

Abstract

...

Description

Onur Başer (MEF Author)
##nofulltext##

Institutional Author Profiles

Başer, Onur

Keywords

Fields of Science

Citation

Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. (November 7-11, 2015). Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. American Heart Association (AHA) Scientific Sessions 2015. Orlando, FL.

WoS Q

Scopus Q

Source

American Heart Association (AHA) Scientific Sessions 2015

Volume

Issue

Start Page

End Page

URI

https://hdl.handle.net/20.500.11779/850

Collections

Ekonomi Bölümü Koleksiyonu
Yükleniyor...
Full item page
Yükleniyor...
Yükleniyor...